Orotral (Risperidone)

Risperidone, the active ingredient in Orotral, is an antipsychotic presented as a tablet for oral use. It is used to manage symptoms of schizophrenia and related psychotic disorders in adults and adolescents. GNH USA supplies Orotral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orotral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Risperidone is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat several psychiatric conditions.

- Schizophrenia: Reduces hallucinations, delusions and thought disorder. - Bipolar I disorder (manic episodes): Stabilises mood and decreases manic symptoms. - Irritable‑behaviour associated with autistic spectrum disorder: Improves irritability and aggression. - Tourette syndrome: Decreases frequency and severity of motor and vocal tics.

Side effects vary in frequency and severity and are monitored during treatment.

Common Side Effects: - Sedation or drowsiness - Weight gain - Increased prolactin levels - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures

Patients should be evaluated for medical history and monitored regularly while using risperidone.

- Cardiovascular assessment: Check for arrhythmias or prolonged QT interval. - Metabolic monitoring: Track weight, fasting glucose and lipid profile. - Endocrine evaluation: Monitor for signs of hyperprolactinemia. - Neurological review: Observe for extrapyramidal signs or movement disorders. - Pregnancy and lactation: Use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Risperidone may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Concomitant use with other antipsychotics combined . - CNS depressants .

Moderate Interactions (Monitor Closely): - CYP2D6 poor‑risk . - Antihypertensive agents. - Anticholinergic drugs. - Medications that prolong . - Alcohol . - Tobacco . - Antifungal . -